The Latin American MS Experts' Forum has developed practical recommendations on the initiation and optimization of disease-modifying therapies in patients with relapsing-remitting multiple sclerosis (RRMS). The recommendations reflect the unique epidemiology of MS and the clinical practice environment in Latin American countries. Treatment response may be evaluated according to changes in relap...

BACKGROUND The presence of asymptomatic spinal cord (SC) lesions in patients with clinically isolated syndrome (CIS) or relapsing-remitting multiple sclerosis (RRMS) predicts conversion to clinically definite multiple sclerosis (CDMS). The relation between asymptomatic SC abnormalities and disability progression warrants further investigation. OBJECTIVE To determine the prognostic value of as...

INTRODUCTION Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system (CNS). Because of limited efficacy and adverse side effects, identifying novel therapeutic and protective agents is important. The aim of this study is to examine the correlations between expanded disability status scale (EDSS) and cytokines after intervention with co-supplemented hemp se...

BACKGROUND Fingolimod is a disease modifying therapy (DMT) in highly active relapsing remitting multiple sclerosis (RRMS), as is natalizumab. Fingolimod decreases annual relapse rates and gadolinium enhancing lesions on MRI as compared to either interferon beta (IFNβ) or placebo. The effect of fingolimod on MRI outcomes compared to natalizumab treatment has not been investigated in (head to hea...

• Multiple sclerosis (MS), a chronic, recurrent infl ammatory disease, is characterized by infl ammatory attacks on central nervous system myelin. Patients with MS experience symptoms such as blurred vision, walking and coordination problems, bladder or bowel dysfunction, numbness, and cognitive impairment.1 • Approximately 85% of patients with MS have relapsing–remitting MS (RRMS), which is ch...

BACKGROUND A possible method of finding physiological markers of multiple sclerosis (MS) is the application of EEG quantification (QEEG) of brain activity when the subject is stressed by the demands of a cognitive task. In particular, modulations of the spectral content that take place in the EEG of patients with multiple sclerosis remitting-relapsing (RRMS) and benign multiple sclerosis (BMS) ...

background:  multiple  sclerosis  (ms) is a  chronic inflammatory  demyelinating  and  neurodegenerative disease  of central  nervous  system  with unknown  causes. etiology of ms involves  both  genetic  and  environment factors.  the  interleukin  7   receptor   (il7r)   gene   is  a promising candidate  for ms, because its involvement in the autoimmunity, regulation of the t-cell homeostasis...

Natalizumab was the first monoclonal antibody to be approved for the treatment of relapsing-remitting multiple sclerosis (RRMS) based on its short-term efficacy and overall tolerability. However, the incidence of treatment-associated progressive multifocal leukoencephalopathy (PML), an infection of the brain caused by the John Cunningham virus, jeopardized this efficacious treatment from the be...

Background Multiple sclerosis (MS) is a chronic, progressive, immune-mediated, neurodegenerative disease of the central nervous system, accumulating patient’s disability over time and causing significant human and economic burden. Approximately 80-90% of the incident MS cases are relapsing-remitting MS (RRMS) characterised by phases of remission and relapse. Important goals of the disease-modif...

Soluble forms of nonclassical human leukocyte antigen (HLA)-G have recently been suggested as immunomodulatory factors in multiple sclerosis (MS). HLA-G inhibits the effecter function of T cells and natural killer (NK) cells. Also regulatory T cells (Treg) are considered as pivotal players in MS pathogenesis. Thus, we aimed to evaluate the presence of HLA-G molecules and Treg cells in Relapsing...